Brief: Olema Oncology Announces New Clinical Trial Agreement With Pfizer To Combine Palazestrant With Atirmociclib In Er+/Her2- Metastatic Breast Cancer
02/09/2025 13:28
Olema Pharmaceuticals Inc OLMA.O: OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL TRIAL AGREEMENT WITH PFIZER TO COMBINE PALAZESTRANT WITH ATIRMOCICLIB IN ER+/HER2- METASTATIC BREAST CANCER OLEMA- UNDER AGREEMENT PFIZER TO SUPPLY ATIRMOCICLIB, OLEMA TO LEAD STUDY Source text: ID:nGNX4B0C9r Further company coverage: OLMA.O
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs